- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03988374
Clinical Efficacy Evaluation of Three Dentifrices
July 27, 2021 updated by: Church & Dwight Company, Inc.
Clinical Efficacy Evaluation of Three Dentifrices Containing 35%, 20%, and 0% Sodium Bicarbonate on the Reduction of Plaque and Gingivitis
Clinical study to evaluate and compare the efficacy of two baking soda containing dentifrices, containing 20% and 35% baking soda, to a non-baking soda dentifrice for their ability to reduce gingivitis and plaque following 6-months of use.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
319
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L4W OC2
- All Sum Research Center Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have provided written informed consent prior to being entered into the study.
- Be between 18 and 70 years of age, male or female.
- Have at least eighteen (18) natural teeth with scorable facial and lingual surfaces as determined by the Examiner. Teeth that are grossly carious, orthodontically banded, exhibiting general cervical abrasion and/or enamel abrasion, or third molars will not be included in the tooth count.
- Have a mean baseline plaque index score ≥ 1.95 as determined by the Soparkar Modification of the Turesky Modification of the Quigley-Hein Plaque Index (Pl).
- Have a mean baseline gingival index score of ≥ l.70 and ≤ 3.0 as determined by the Modified Gingival Index (MGI).
- Presence of ≥ 10 bleeding sites upon probing.
- Agree not to have a dental prophylaxis or any other elective, non-emergency dental procedures any time during the study.
- Agree to abstain from the use of chewing gum, mouth rinses, any toothpaste other than the study toothpaste, tooth whitening products (either professional or at home use) and all other oral hygiene other than the study procedures for the duration of the study.
- Agree to refrain from all oral hygiene on the morning of each evaluation visit and to refrain from eating, drinking, and smoking for 4 hrs, prior to each evaluation visit.
- Agree to comply with the conditions and schedule of the study.
Exclusion Criteria:
- Physical limitations or restrictions that might preclude normal tooth brushing.
- Evidence of gross oral pathology, including widespread caries or chronic neglect, extensive restoration, preexisting gross plaque or soft or hard tissue tumor of the oral cavity.
- Heavy supra- or subgingival calculus that might interfere with evaluations as determined by the Investigator/Examiner.
- Evidence of major oral hard or soft tissue lesions or trauma at the baseline visit as determined by the Investigator/Examiner.
- Conditions requiring antibiotic treatment prior to dental procedures.
- History of uncontrolled diabetes or hepatic or renal disease, or other serious conditions or transmittable diseases, (e.g. cardiovascular disease, AIDS).
- Subjects with grossly carious, fully crowned, or extensively restored teeth, orthodontic appliances, peri/oral piercings, or removable partial dentures.
- Treatment with antibiotics within the 1-month period before the baseline examination, or a condition that is likely to require antibiotic treatment over the course of the trial.
- Chronic treatment (2 weeks or more) with any medication known to affect periodontal status (including phenytoin, calcium antagonists, cyclosporine, coumarin, nonsteroidal anti-inflammatory drugs, and aspirin) within 1 month of the baseline examination. All other medications for chronic medical conditions must have been initiated at least 3 months before enrollment.
- Have severe periodontal disease or being actively treated for periodontal disease.
- Having history of early-onset periodontitis or acute necrotizing ulcerative gingivitis.
- Concomitant periodontal therapy other than prophylaxis in the last 6 months.
- Professional prophylaxis within 1 month prior to the baseline clinical evaluation.
- Subjects who participated in a gingivitis study in the past month.
- Daily use of chemotherapeutic antiplaque/antigingivitis products within the past 4 months.
- History of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses.
- Subjects who are allergic to any ingredients in the test or control product, as listed on the IRB Safety Assessment.
- Self-reported pregnancy and nursing since hormonal changes can exaggerate gingival response to dental plaque.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 0% Baking Soda Dentifrice
|
Dentifrice on plaque, gingivitis, and bleeding.
|
Active Comparator: 20% Baking Soda Dentifrice
|
Dentifrice on plaque, gingivitis, and bleeding.
|
Active Comparator: 35% Baking Soda Dentifrice
|
Dentifrice on plaque, gingivitis, and bleeding.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Within-Treatment Whole-Mouth Score - Gingival Efficacy
Time Frame: baseline, six weeks, 3 months and 6 months
|
Mean Within-Treatment Whole-Mouth Score as measured by Gingival Index (0=absence of inflammation, 1=mild inflammation: slight change in color, little change in texture of any portion of but not the entire marginal or papillary gingival unit, 2=mild inflammation: slight change in color, little change in texture to entire marginal or papillary gingival unit, 3=moderate inflammation: glazing, redness, edema and/or hypertrophy of the marginal or papillary gingival unit, 4=severe inflammation: marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration.
The scale ranges from 0-4.
|
baseline, six weeks, 3 months and 6 months
|
Mean Within-Treatment Whole-Mouth Score - Gingival Bleeding Efficacy
Time Frame: baseline, six week, three months, and six months
|
Mean Within-Treatment Whole-Mouth Score as measured by Gingival Bleeding Index (0=absence of bleeding after 30 seconds, 1= bleeding observed after 30 seconds, 2= bleeding occurs instantly).
The scale ranges from 0-2.
|
baseline, six week, three months, and six months
|
Mean Within-Treatment Whole-Mouth Score - Plaque Efficacy
Time Frame: baseline, six weeks, three months, and six months
|
Mean Within-Treatment Whole-Mouth Score as measured by Plaque Index (0=no visible plaque, 1=separate flecks of plaque at the cervical margin of the tooth, 2=a thin, continuous band of plaque (up to 1mm wide) at the cervical margin, 3= a band of plaque wider than 1 mm but covering less than one-third of the crown, 4=plaque covering at least one-third but less than two-thirds of the crown, 5= plaque covering two-thirds or more of the crown).
The scale ranges from 0-5.
|
baseline, six weeks, three months, and six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 22, 2018
Primary Completion (Actual)
August 24, 2018
Study Completion (Actual)
August 24, 2018
Study Registration Dates
First Submitted
April 4, 2019
First Submitted That Met QC Criteria
June 13, 2019
First Posted (Actual)
June 17, 2019
Study Record Updates
Last Update Posted (Actual)
August 23, 2021
Last Update Submitted That Met QC Criteria
July 27, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ST-7700
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dental Plaque
-
Azienda Ospedaliera Città della Salute e della...Recruiting
-
Colgate PalmoliveCompleted
-
Church & Dwight Company, Inc.Completed
-
Damascus UniversityCompletedPlaque, DentalSyrian Arab Republic
-
Church & Dwight Company, Inc.Completed
-
Church & Dwight Company, Inc.CompletedPlaque, DentalUnited States
-
Colgate PalmoliveCompleted
-
Multan Medical And Dental CollegeUnknown
-
Marmara UniversityCompletedPlaque, DentalTurkey
-
Heba sabbaghCompleted
Clinical Trials on Dentifrices
-
Church & Dwight Company, Inc.CompletedPlaque, DentalUnited States
-
University of TalcaFederal University of Rio Grande do SulCompleted
-
University of Sao PauloCompletedDentin HypersensitivityBrazil
-
Dow University of Health SciencesCompletedDentin HypersensitivityPakistan
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedDental Caries | Dental FluorosisBrazil